EAM
NXTC icon

Exome Asset Management’s NextCure NXTC Stock Holding History

Exome Asset Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Sell
115,500
-49,500
-30% -$605K 0.63% 49
2025
Q4 		$2.34M Buy
+165,000
New +$1.71M 1.12% 36

Other funds holding NXTC

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Exome Asset Management's NXTC Position: Q1 2026 in Review

Exome Asset Management reduced its NextCure (NXTC) stake by 30% in Q1 2026, selling an estimated $605K and leaving 115,500 shares worth $1.22M. The position accounts for 0.63% of the portfolio, ranked #49.

Exome Asset Management first reported a position in NXTC in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.34M in Q4 2025. 26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Exome Asset Management held 115,500 shares of NextCure worth $1.22M as of Q1 2026.
  • Exome Asset Management sold 49,500 NextCure shares in Q1 2026, an estimated $605K.
  • NextCure made up 0.63% of Exome Asset Management's portfolio in Q1 2026, its #49 holding.
  • Exome Asset Management first reported a position in NextCure in Q4 2025 and has held it in 2 quarters since.
  • Exome Asset Management's NextCure position peaked at $2.34M in Q4 2025.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.